Succinimide

Succinimide

SCHEMBL132748

O=C(O)CCCc1ccc(N2C(=O)C=CC2=O)cc1.O=C1CCC(=O)N1

nearest known ligand 0.49

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 5/20 0.49
FAAH O00519 3/20 0.49
RXRA P19793 2/20 0.48
RXRB P28702 2/20 0.48
RXRG P48443 2/20 0.48
TBXAS1 P24557 2/20 0.44
HDAC3 O15379 1/20 0.44
MAPK1 P28482 1/20 0.44
ADRA1A P35348 1/20 0.44
HDAC4 P56524 1/20 0.44
SLC6A3 Q01959 1/20 0.44
HDAC1 Q13547 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC10 Q969S8 1/20 0.44
HDAC11 Q96DB2 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
HDAC9 Q9UKV0 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28349233 0.92 MGLL (0.44) MGLLFAAHRXRARXRBRXRG
SCHEMBL514697 0.89 MGLL (0.59) MGLLFAAHRXRARXRBRXRG
Hydrochloric Acid SCHEMBL28737900 0.87 MGLL (0.58) MGLLFAAHRXRARXRBRXRG
Hydrazine SCHEMBL27822007 0.86 MGLL (0.56) MGLLFAAHRXRARXRBRXRG
SCHEMBL8510655 0.84 MGLL (0.49) MGLLFAAHRXRARXRBRXRG
SCHEMBL2347571 0.82 MGLL (0.40) MGLLFAAHRXRARXRBRXRG
SCHEMBL1823484 0.80 PPARD (0.62) MGLLFAAHMAPK1PPARDPPARA
SCHEMBL20053772 0.79 RXRA (0.56) RXRARXRBRXRGTBXAS1HDAC3
SCHEMBL741572 0.77 MGLL (0.59) MGLLFAAHRXRARXRBRXRG
Phenylbutanoic Acid SCHEMBL22157891 0.77 HDAC3 (0.53) HDAC3MAPK1ADRA1AHDAC4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 497 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4743076-A2 SYNTHETIC BI-FUNCTIONAL DEGRADERS OF INTEGRINS The Board of Trustees of the Leland Stanford Junior University (US) 2026-05-20 EP disclosed
EP-3600372-B1 SYNTHEKINE COMPOSITIONS AND METHODS OF USE UNIV LELAND STANFORD JUNIOR (US) 2026-05-13 EP disclosed
EP-4739804-A1 METHODS AND COMPOSITIONS FOR CHARACTERIZING VIRAL PARTICLES IN A BIOLOGICAL SAMPLE NanoMosaic Inc. (US) 2026-05-13 EP disclosed
US-20260108469-A1 COMPOSITIONS COMPRISING WATER INSOLUBLE DRUGS AND METHODS OF PRODUCING AND USING SAME NANO GHOST LTD (IL) 2026-04-23 US disclosed
US-20260091143-A1 NEAR-INFRARED IMAGING AGENT AND USES THEREOF UNIV CASE WESTERN RESERVE (US) 2026-04-02 US disclosed
US-12466884-B2 Tissue-specific WNT signal enhancing molecules and uses Surrozen Operating, Inc. (US) 2025-11-11 US disclosed
US-12453762-B2 Complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for treatment of glioblastoma AMAL THERAPEUTICS SA (CH) 2025-10-28 US disclosed
US-20250304702-A1 WNT SIGNALING AGONIST MOLECULES UNIVERSITY OF WASHINGTON 2025-10-02 US disclosed
US-20250250329-A1 CYTOKINE ADAPTOR PROTEINS AND USES THEREOF HOWARD HUGHES MEDICAL INSTITUTE 2025-08-07 US disclosed
EP-4590179-A1 NEAR-INFRARED IMAGING AGENT AND USES THEREOF CASE WESTERN RESERVE UNIVERSITY (US) 2025-07-30 EP disclosed
US-5869040-A ADMINISTERING INTERFERING MUTANT PROTO-ONCOGENE OR ONCOPROTEIN TO TARGET CELL BIOGEN, INC (US) 1999-02-09 US disclosed
EP-0656950-B1 TAT-DERIVED TRANSPORT POLYPEPTIDES BIOGEN INC (US) 1998-11-04 EP disclosed
US-5804604-A AGENT FOR INTRACELLULAR DELIVERY OF CARGO MOIETY BIOGEN, INC. (US) 1998-09-08 US disclosed
US-5747641-A CARGO MOLECULE CONJUGATED TO TRANSPORT POLYPEPTIDE HAVING ABSENCE OF CYSTEINE RICH POLYPEPTIDE REGIONS FOR REDUCED DISULFIDE AGGREGATION AND TRANS-ACTIVATION; INTRACELLULAR DELIVERY BIOGEN MA INC. 1998-05-05 US disclosed
WO-1997034473-A9 CRAF1 (TRAF-3) ISOFORMS AND USES THEREOF 1998-04-02 WO disclosed
WO-1997043416-A1 COMMON GAMMA CHAIN BLOCKING AGENTS BIOGEN, INC. (US) 1997-11-20 WO disclosed
US-5674980-A Fusion protein comprising tat-derived transport moiety BIOGEN IDEC MA, INC. 1997-10-07 US disclosed
WO-1997034473-A1 CRAF1 (TRAF-3) ISOFORMS AND USES THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 1997-09-25 WO disclosed
US-5670617-A PROTEINS AND SINGLE-STRANDED OR DOUBLE STRANDED NUCLEIC ACID BIOGEN IDEC MA, INC. 1997-09-23 US disclosed
US-5652122-A Nucleic acids encoding and methods of making tat-derived transport polypeptides BIOGEN IDEC MA, INC. 1997-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260108469-A1 COMPOSITIONS COMPRISING WATER INSOLUBLE DRUGS AND METHODS OF PRODUCING AND USING SAME ABCB1, WEE1, PARP3 MGLL 3818/4885FAAH 4554/4885RXRA 4462/4885
US-20250250329-A1 CYTOKINE ADAPTOR PROTEINS AND USES THEREOF IL6ST, TNFRSF1A, TRAF6 MGLL 4166/4885FAAH 3763/4885RXRA 2860/4885
US-20260091143-A1 NEAR-INFRARED IMAGING AGENT AND USES THEREOF IGSF11, VSIR, FCGR3B MGLL 1494/4885FAAH 2469/4885RXRA 1636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.